An electric comb that delivers brief electrical pulses and two experimental genetic agents to the scalp regrew hair across 97.85 percent of the treated area in mice within 28 days, outperforming minoxidil and finasteride in the same animal model, researchers at Beihang University in Beijing reported, according to Fr.
The device, named “Detangle,” combines unevenly spaced teeth that act as electrodes with channels that release a VEGF-A plasmid and an siRNA targeting the SRD5A2 gene.
The electrical field generated between the mismatched teeth is 2.63 times stronger and penetrates about nine times deeper — reaching roughly 660 micrometers versus 74 micrometers for topical application alone — enabling electroporation that drives the nucleic acids into hair-follicle cells, according to the study published in Nature Communications. The authors wrote that “safe and efficient drug delivery remains the key to treatment success in androgenetic alopecia.”
Male mice with testosterone-induced androgenetic alopecia were treated every three days for four weeks. Untreated animals showed about 1 percent hair coverage; electrical stimulation alone reached roughly 40 percent; finasterid achieved about 50 percent; minoxidil about 70 percent; and the full combination 97.85 percent, N-TV reported citing the study data.
The authors said that more than 1.5 billion people worldwide are affected by androgenetic alopecia. Dihydrotestosterone, or DHT, plays an important role; it is formed from testosterone and can cause hair follicles to shrink gradually in genetically susceptible people.
The VEGF-A plasmid aims to spur angiogenesis around follicles, while the siRNA suppresses 5-alpha-reductase 2, the enzyme that converts testosterone into dihydrotestosterone (DHT), the hormone that shrinks genetically susceptible follicles. Tissue analysis also pointed to activation of the Wnt/beta-catenin pathway, which governs follicle regeneration, Scinexx reported.
The electrical stimulation also facilitated uptake into hair-follicle cells. The combination of both molecules achieved more hair growth than either agent delivered alone. Tissue analyses further showed improved local blood flow and more and more strongly activated hair follicles.

No acute skin irritation or significant changes in inflammatory markers were observed after repeated applications in the mice, Scinexx noted.
However, the authors cautioned that the model uses experimentally induced hair loss on back skin over weeks, not the years-long progressive miniaturization seen in human androgenetic alopecia, and the long-term safety of repeated DNA and RNA delivery to the human scalp remains unknown, according to N Tv. Further preclinical work and clinical trials are required before any human use can be considered.